Intrahepatic Cholangiocarcinoma

Ramy El-Diwany; Timothy M. Pawlik; Aslam Ejaz

doi:10.1016/j.soc.2019.06.002

Intrahepatic Cholangiocarcinoma

Ramy El-Diwany
, Timothy M. Pawlik
, Aslam Ejaz

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic and extrahepatic bile ducts and occurs proximal to the segmental biliary ducts. Risk factors include chronic hepatitis and cirrhosis, biliary inflammatory diseases, and hepatobiliary flukes, although in most cases, no known risk factor is identified. ICC is highly aggressive, with long-term survival only observed in patients with a complete R0 surgical resection. Technical and physiologic resectability should be considered when performing an operative plan. Nodal involvement is among the most important prognostic factors associated with survival and a porta hepatis lymphadenectomy should be performed at the time of resection. Adjuvant chemotherapy can provide a significant survival benefit for patients with more advanced or aggressive tumors. Systemic, locoregional, and targeted therapies exist for patients with unresectable or metastatic disease.

Original language	English (US)
Pages (from-to)	587-599
Number of pages	13
Journal	Surgical Oncology Clinics of North America
Volume	28
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2019.06.002
State	Published - Oct 2019

Keywords

Cholangiocarcionma
Hepatobiliary
Intrahepatic cholangiocarcinoma

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2019.06.002

Cite this

@article{0cc73f28158a4e8c833cd6f9d2e8bdc3,

title = "Intrahepatic Cholangiocarcinoma",

abstract = "Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic and extrahepatic bile ducts and occurs proximal to the segmental biliary ducts. Risk factors include chronic hepatitis and cirrhosis, biliary inflammatory diseases, and hepatobiliary flukes, although in most cases, no known risk factor is identified. ICC is highly aggressive, with long-term survival only observed in patients with a complete R0 surgical resection. Technical and physiologic resectability should be considered when performing an operative plan. Nodal involvement is among the most important prognostic factors associated with survival and a porta hepatis lymphadenectomy should be performed at the time of resection. Adjuvant chemotherapy can provide a significant survival benefit for patients with more advanced or aggressive tumors. Systemic, locoregional, and targeted therapies exist for patients with unresectable or metastatic disease.",

keywords = "Cholangiocarcionma, Hepatobiliary, Intrahepatic cholangiocarcinoma",

author = "Ramy El-Diwany and Pawlik, \{Timothy M.\} and Aslam Ejaz",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

doi = "10.1016/j.soc.2019.06.002",

language = "English (US)",

volume = "28",

pages = "587--599",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Intrahepatic Cholangiocarcinoma

AU - El-Diwany, Ramy

AU - Pawlik, Timothy M.

AU - Ejaz, Aslam

PY - 2019/10

Y1 - 2019/10

N2 - Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic and extrahepatic bile ducts and occurs proximal to the segmental biliary ducts. Risk factors include chronic hepatitis and cirrhosis, biliary inflammatory diseases, and hepatobiliary flukes, although in most cases, no known risk factor is identified. ICC is highly aggressive, with long-term survival only observed in patients with a complete R0 surgical resection. Technical and physiologic resectability should be considered when performing an operative plan. Nodal involvement is among the most important prognostic factors associated with survival and a porta hepatis lymphadenectomy should be performed at the time of resection. Adjuvant chemotherapy can provide a significant survival benefit for patients with more advanced or aggressive tumors. Systemic, locoregional, and targeted therapies exist for patients with unresectable or metastatic disease.

AB - Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic and extrahepatic bile ducts and occurs proximal to the segmental biliary ducts. Risk factors include chronic hepatitis and cirrhosis, biliary inflammatory diseases, and hepatobiliary flukes, although in most cases, no known risk factor is identified. ICC is highly aggressive, with long-term survival only observed in patients with a complete R0 surgical resection. Technical and physiologic resectability should be considered when performing an operative plan. Nodal involvement is among the most important prognostic factors associated with survival and a porta hepatis lymphadenectomy should be performed at the time of resection. Adjuvant chemotherapy can provide a significant survival benefit for patients with more advanced or aggressive tumors. Systemic, locoregional, and targeted therapies exist for patients with unresectable or metastatic disease.

KW - Cholangiocarcionma

KW - Hepatobiliary

KW - Intrahepatic cholangiocarcinoma

UR - https://www.scopus.com/pages/publications/85071390578

UR - https://www.scopus.com/pages/publications/85071390578#tab=citedBy

U2 - 10.1016/j.soc.2019.06.002

DO - 10.1016/j.soc.2019.06.002

M3 - Review article

C2 - 31472907

AN - SCOPUS:85071390578

SN - 1055-3207

VL - 28

SP - 587

EP - 599

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

Intrahepatic Cholangiocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this